Poor outcomes include lower response rate to chemotherapy, higher mortality, recurrence.
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
Avelumab improves overall and progression-free survival among patients with unresectable locally advanced or metastatic urothelial carcinoma whose disease has not progressed while on first-line chemotherapy.
PPI use linked to significantly worse progression-free, overall survival in advanced urothelial cancer.
Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.
The purpose of this trial was to determine if suppression of MDSCs with acalabrutinib could enhance pembrolizumab activity safely in this population.
Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.
Multiparametric magnetic resonance imaging is highly accurate in differentiating nonmuscle-invasive from muscle-invasive bladder cancer, according to a new systematic review and meta-analysis.
The 20-year mortality rate among patients with muscle-invasive bladder cancer is 71%, according to a study of Swedish patients. Investigators who analyzed a large population-based cohort of patients with bladder cancer that had more than 20 years of follow-up found that muscle-invasive bladder cancer (MIBC) results in a high risk of cancer-specific death, according to…
The FDA has approved Bavencio® (avelumab; EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.